대한뉴팜

Daehan Nupharm has completed the construction of its new GMP-certified production plant with a total floor area of 15,150 square meters, marking a significant step forward in the company’s journey to become a global pharmaceutical and biotech leader.

The new facility was completed through a 14month process that began with conceptual design in February 2023, followed by a groundbreaking ceremony in May and the start of construction in June of the same year. More than 35,000 workers participated in the project, with a total investment of approximately KRW 81 billion.



 

The state-of-the-art plant is equipped with an injectable production line that fully complies with the EU GMP Annex 1 guidelines, as well as a solid dosage production line incorporating a BIN system to minimize exposure. Once fully operational, the facility will have the capacity to produce 800 million tablets and 200 million capsules annually. Validation and product transfer processes are currently underway, with full-scale operations scheduled to begin in January 2027.
 

This new plant represents the second phase of the “Hyangnam Project 1·2·3”, which began in 2022. Phase 1, the R&D center, was completed in June 2023, and Phase 3 will involve the construction of an automated warehouse. The Phase 2 GMP facility is regarded as a pivotal milestone in this long-term strategic initiative.
 

The completion of the new facility is the result of years of preparation and investment. Daehan Nupharm plans to complete product transfer seamlessly and begin producing new R&D pipeline products at the plant. Beyond simply expanding production capacity, this facility will serve as a solid foundation for the stable supply of high-quality pharmaceuticals and expansion into global markets.
 

Looking ahead, Daehan Nupharm will continue to strengthen its R&D capabilities and accelerate its growth as a global pharmaceutical and biotech company.